Aspirin
A phase II double-blind placebo RCT recruited 94 patients to receive
aspirin 975 mg twice daily, before and after their cisplatin dose.
Patients in the aspirin arm were more commonly affected by aspirin renal
toxicity(17.8% vs 10.2%) and no protective hearing effect was observed
(p= 0.233)(Crabb et al., 2017).